SUPN SUPERNUS PHARMACEUTICALS, INC.

8-K Current Report

Filed: February 24, 2026

Health Care

Pharmaceutical Preparations

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 or full-year 2025 earnings results reported; filing signed February 24, 2026 by CFO Timothy C. Dec
• Actual financial figures contained in referenced exhibit — investor should review attached press release for revenue, EPS, and guidance details

Other SUPERNUS PHARMACEUTICALS, INC. 8-K Filings

8-K Feb 24, 2026

Get deeper insights on SUPERNUS PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.